Lu AF95245
Phase 3Small molecule
LundbeckLu AF95245 is one of 424 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.
15
Indications
75
Total Trials
5
Active Trials
423
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Lu AF95245
LundbeckPhase 3
Celexa
AbbViePreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Permax
VValeant Pharmaceuticals
Preclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Compazine
GGlaxo Dba Glaxosmithkline
Preclinical
Persantine
Boehringer IngelheimPreclinical
Inversine
TTargacept Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia8 trials
Show 5 more trials
ART4 trials
Women4 trials
Adult4 trials
Alzheimer's Disease3 trials
32 more indications
Major Depressive Disorder3 trials
AIN3 trials
Migraine3 trials
Efficacy and Safety2 trials
Parkinson's Disease (PD)2 trials
Ischemic stroke2 trials
Cognitive impairment1 trial
Impairment1 trial
Schizoaffective Disorder1 trial
Ataxia1 trial
Post-Traumatic Stress Disorder, PTSD1 trial
Thyroid Eye Disease1 trial
Congenital Adrenal Hyperplasia1 trial
Multiple Sclerosis1 trial
Parkinson's Disease1 trial
Generalized Anxiety Disorder1 trial
Allergies1 trial
Hepatic Impairment1 trial
Oral1 trial
Alzheimer's Disease (AD)1 trial
Tics1 trial
Unspecified11 trials
Show 8 more trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lu AF95245. EMBL-EBI & Wellcome Sanger Institute.
- [4]